L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells

Cell Death and Differentiation

Volumn 22, Issue 1, 2015, Pages 118-130

  Ayroldi, E ^a   Petrillo, M G ^a   Bastianelli, A ^a   Marchetti, M C ^a   Ronchetti, S ^a   Nocentini, G ^a   Ricciotti, L ^a   Cannarile, L ^a   Riccardi, C ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; GLUCOCORTICOID; LEUCINE ZIPPER PROTEIN; LONG GLUCOCORTICOID INDUCED LEUCINE ZIPPER; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; DSIP1 PROTEIN, MOUSE; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; ONCOPROTEIN; PUMA PROTEIN, MOUSE; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TSC22D3 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOMA CELL LINE; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION; XENOGRAFT; ANIMAL; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; MALE; METABOLISM; PROTEIN STABILITY; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84926631512     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.129     Document Type: Article

References (59)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
3. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12: 2973-2983.
4. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
5. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
7. Van Dyke T. p53 and tumor suppression. N Engl J Med 2007; 356: 79-81.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
9. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010; 17: 93-102.
10. Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2000; 2: 563-568.
11. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000; 2: 569-573.
12. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999; 18: 1660-1672.
13. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
14. Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518-530.
15. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-812.
16. Cannarile L, Zollo O, D'Adamio F, Ayroldi E, Marchetti C, Tabilio A et al. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene. Cell Death Differ 2001; 8: 201-203.
17. Bruscoli S, Donato V, Velardi E, Di Sante M, Migliorati G, Donato R et al. Glucocorticoidinduced leucine zipper (GILZ) and long GILZ inhibit myogenic differentiation and mediate anti-myogenic effects of glucocorticoids. J Biol Chem 2010; 285: 10385-10396.
18. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009; 23: 3649-3658.
19. Beaulieu E, Morand EF. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat Rev Rheumatol 2011; 7: 340-348.
20. Ayroldi E, Migliorati G, Bruscoli S, Marchetti C, Zollo O, Cannarile L et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood 2001; 98: 743-753.
21. Cannarile L, Fallarino F, Agostini M, Cuzzocrea S, Mazzon E, Vacca C et al. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. Blood 2006; 107: 1039-1047.
22. Cannarile L, Cuzzocrea S, Santucci L, Agostini M, Mazzon E, Esposito E et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology 2009; 136: 530-541.
23. Pinheiro I, Dejager L, Petta I, Vandevyver S, Puimege L, Mahieu T et al. LPS resistance of SPRET/Ei mice is mediated by Gilz, encoded by the Tsc22d3 gene on the X chromosome. EMBO Mol Med 2013; 5: 456-470.
24. Ayroldi E, Zollo O, Bastianelli A, Marchetti C, Agostini M, Di Virgilio R et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Investig 2007; 117: 1605-1615.
25. Bruscoli S, Velardi E, Di Sante M, Bereshchenko O, Venanzi A, Coppo M et al. Long glucocorticoid-induced leucine zipper (L-GILZ) protein interacts with ras protein pathway and contributes to spermatogenesis control. J Biol Chem 2012; 287: 1242-1251.
26. Sengupta S, Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann NY Acad Sci 2004; 1024: 54-71.
27. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
28. Sasson R, Tajima K, Amsterdam A. Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2. Endocrinology 2001; 142: 802-811.
29. Yu C, Yap N, Chen D, Cheng S. Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53. Cancer Lett 1997; 116: 191-196.
30. Crochemore C, Michaelidis TM, Fischer D, Loeffler JP, Almeida OF. Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation. FASEB J 2002; 16: 761-770.
31. Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM et al. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 2003; 278: 9747-9753.
32. Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ et al. Tumor suppressor protein (p)53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci USA 2011; 108: 17117-17122.
33. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J et al. Direct observation of individual endogenous protein complexes In situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
34. Sandy P, Gostissa M, Fogal V, Cecco LD, Szalay K, Rooney RJ et al. p53 is involved in the p120E4F-mediated growth arrest. Oncogene 2000; 19: 188-199.
35. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-4114.
36. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-9117.
37. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-442.
38. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
39. Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J et al. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wildtype p53 breast cancer cells. Int J Oncol 2013; 43: 1935-1942.
40. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
41. Kruse JP, Gu W. SnapShot: p53 posttranslational modifications. Cell 2008; 133: 930-930 e931.
42. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004; 36: 147-150.
43. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92.
44. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998; 18: 7288-7293.
45. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302: 1972-1975.
46. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P et al. Differentiation of Hdm2- mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002; 99: 14734-14739.
47. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
48. Brooks CL, Li M, Hu M, Shi Y, Gu W. The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007; 26: 7262-7266.
49. Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 2010; 16: 2949-2958.
50. Yoon CH, Rho SB, Kim ST, Kho S, Park J, Jang IS et al. Crucial role of TSC-22 in preventing the proteasomal degradation of p53 in cervical cancer. PloS One 2012; 7: e42006.
51. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 451: 76-80.
52. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010; 140: 384-396.
53. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
54. Wang S, El-Deiry WS. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 2006; 66: 6982-6989.
55. Deffie A, Wu H, Reinke V, Lozano G. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 1993; 13: 3415-3423.
56. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 14973-14977.
57. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Investig 1999; 104: 263-269.
58. Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 2012; 4: 298-312.
59. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoidinduced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-7941.